ReviewJournal of inflammation research2026
The NLRP3-α-Synuclein Circuit: A Core Driver and Therapeutic Target in Parkinson's Disease.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neuroinflammatory mechanisms underlying Parkinson's disease (PD) have evolved from a view of localized central events to a systemic network perspective involving "brain-periphery" interactions. The NLRP3 inflammasome, as a core component of the innate immune system, plays a pivotal role within this network. This review aims to systematically elucidate NLRP3's multifaceted roles in PD: First, it delves into the "self-amplifying" vicious cycle between α-synuclein pathology and NLRP3 activation, supports the hypothesis that this cycle may serve as a core engine. Second, it transcends central nervous system limitations to systematically examine how the central-peripheral immune interaction network-comprising gut microbiota and peripheral immune cells-regulates this cycle. Third, it objectively evaluates the potential and current limitations of NLRP3 pathway-associated molecules as biomarkers for disease diagnosis and progression monitoring. Fourth, it comprehensively reviews therapeutic strategies targeting NLRP3 and critically examines key challenges in their clinical translation. This paper provides an integrated perspective for understanding PD as a systemic inflammatory disease and offers a theoretical framework for future biomarker development and precision treatment strategies based on this pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.